Moreover, OC suppressed its target, c-Met, in in vivo multiple human BC phenotypes xenografted in nude mice and selectively suppressed the malignancy progression at tolerated daily oral doses of 10 mg/kg and 5 mg/kg intraperitoneally 3×/week [17,18,23,35,36]. The gene discussed is MET; the disease is breast cancer.